Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Although the antistaphylococcal penicillins remain the drugs of choice for methicillin-susceptible Staphylococcus aureus (MSSA) infections, cefazolin and ceftriaxone are often prescribed due to their less frequent dosing and reduced cost. The purpose of this study was to compare clinical outcomes and adverse events in patients receiving outpatient parenteral antimicrobial therapy (OPAT) with ceftriaxone or cefazolin for the treatment of MSSA infections.
A retrospective study was carried out of 122 patients evaluated at Ben Taub and Lyndon B. Johnson General Hospitals in Houston, Texas, between January 1, 2006, and March 31, 2012, with a documented MSSA infection who received cefazolin or ceftriaxone as OPAT. A favorable clinical outcome was determined by their primary care physician’s assessment at follow-up in the clinic.
Out of 122 patients, 78 (64 %) were treated with cefazolin and 44 (36 %) with ceftriaxone. Patients were predominantly young (median age 46 years), male (54.2 %), and Hispanic (51.2 %). Patients were similar in terms of baseline demographics, types of infections, and management of infections. Favorable clinical outcomes were similar between cefazolin and ceftriaxone (67.9 versus 79.8 %, p = 0.17), along with a similar incidence of adverse events and complications (5.1 versus 2.3 %, p = 0.65, and 26.9 versus 18.2 %, p = 0.38, respectively).
OPAT with either cefazolin or ceftriaxone is similar in terms of favorable outcomes, adverse events, and complications when treating MSSA infections. A randomized clinical trial is needed in order to confirm these results.
- Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40: pp. 373-383 CrossRef
- Cox, AM, Malani, PN, Wiseman, SW, Kauffman, CA (2007) Home intravenous antimicrobial infusion therapy: a viable option in older adults. J Am Geriatr Soc 55: pp. 645-650 CrossRef
- Durack, DT, Lukes, AS, Bright, DK (1994) New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 96: pp. 200-209 CrossRef
- Guglielmo, BJ, Luber, AD, Paletta, D, Jacobs, RA (2000) Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 30: pp. 205-207 CrossRef
- Knaus, WA, Draper, EA, Wagner, DP, Zimmerman, JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: pp. 818-829 CrossRef
- Nannini, EC, Singh, KV, Murray, BE (2003) Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis 37: pp. 1194-1198 CrossRef
- Nannini, EC, Stryjewski, ME, Singh, KV, Bourgogne, A, Rude, TH, Corey, GR, Fowler, VG, Murray, BE (2009) Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother 53: pp. 3437-3441 CrossRef
- Nicholson, SC, Welte, T, File, TM, Strauss, RS, Michiels, B, Kaul, P, Balis, D, Arbit, D, Amsler, K, Noel, GJ (2012) A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 39: pp. 240-246 CrossRef
- Paul, M, Zemer-Wassercug, N, Talker, O, Lishtzinsky, Y, Lev, B, Samra, Z, Leibovici, L, Bishara, J (2010) Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?. Clin Microbiol Infect 17: pp. 1581-1586 CrossRef
- Quinn, EL, Pohlod, D, Madhavan, T, Burch, K, Fisher, E, Cox, F (1973) Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J Infect Dis 128: pp. S386-S391 CrossRef
- Sutherland, R, Croydon, EA, Rolinson, GN (1970) Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin. Br Med J 4: pp. 455-460 CrossRef
- Tice, AD, Hoaglund, PA, Shoultz, DA (2003) Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 114: pp. 723-728 CrossRef
- Tice, AD, Hoaglund, PA, Shoultz, DA (2003) Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 51: pp. 1261-1268 CrossRef
- Tice, AD, Rehm, SJ, Dalovisio, JR, Bradley, JS, Martinelli, LP, Graham, DR, Gainer, RB, Kunkel, MJ, Yancey, RW, Williams, DN (2004) Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 38: pp. 1651-1672 CrossRef
- Wieland, BW, Marcantoni, JR, Bommarito, KM, Warren, DK, Marschall, J (2012) A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 54: pp. 585-590 CrossRef
- Winters RW, Parver AK, Sansbury JD. Home infusion therapy: a service and demographic profile: a report for the National Alliance for Infusion Therapy. Washington, DC: National Alliance for Infusion Therapy; 1992. p. 1–61.
- Wynn, M, Dalovisio, JR, Tice, AD, Jiang, X (2005) Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South Med J 98: pp. 590-595 CrossRef
- Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone
Volume 41, Issue 4 , pp 769-774
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Staphylococcus aureus
- Industry Sectors
- Author Affiliations
- 1. Department of Pharmacy, Harris County Hospital District, 1504 Taub Loop, Houston, TX, 77030, USA
- 2. Department of Pharmacy Practice, Texas A&M Health Science Center Rangel College of Pharmacy, 5656 Kelley Street, Houston, TX, 77026, USA
- 3. Department of Medicine, Division of Infectious Diseases, University of Texas Health Sciences Center, 6431 Fannin Street, Houston, TX, 77030, USA